title: Fatal immune hemolytic anemia due to cefotetan.
abstract: In the first death associated with immune hemolytic anemia due to cefotetan, the patient developed hemolytic anemia and renal failure, dying 12 days after the beginning of 1 week's cefotetan therapy. The patient's serum contained strong antibodies reacting with cefotetan-treated red cells (RBCs) and with uncoated RBCs in the presence of cefotetan; a much weaker, drug-independent antibody was also detected. Three-days before the patient's death, the antibody reacting with cefotetan-coated RBCs rose to a titer of 262,144; the titer of the antibody to uncoated RBCs, in the presence of cefotetan, rose to 2048; the titer of the drug-independent antibody remained at 4.
authors.affiliation: American Red Cross Blood Center, Los Angeles-Orange Counties Region, California.
authors.forename: G
authors.initials: G
authors.lastname: Garratty
authors.forename: S
authors.initials: S
authors.lastname: Nance
authors.forename: M
authors.initials: M
authors.lastname: Lloyd
authors.forename: R
authors.initials: R
authors.lastname: Domen
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000401:mortality; D015313:Cefotetan / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D003298:Coombs Test; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D015313:Cefotetan